173 related articles for article (PubMed ID: 29794816)
1. Antiretroviral implants for treatment and prevention of HIV infection.
Flexner C
Curr Opin HIV AIDS; 2018 Jul; 13(4):374-380. PubMed ID: 29794816
[TBL] [Abstract][Full Text] [Related]
2. Long-acting implants to treat and prevent HIV infection.
Weld ED; Flexner C
Curr Opin HIV AIDS; 2020 Jan; 15(1):33-41. PubMed ID: 31764198
[TBL] [Abstract][Full Text] [Related]
3. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis.
Flexner C; Thomas DL; Swindells S
Curr Opin HIV AIDS; 2019 Jan; 14(1):13-20. PubMed ID: 30394948
[TBL] [Abstract][Full Text] [Related]
4. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
Flexner C; Owen A; Siccardi M; Swindells S
Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
[TBL] [Abstract][Full Text] [Related]
5. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.
Simpson SM; Widanapathirana L; Su JT; Sung S; Watrous D; Qiu J; Pearson E; Evanoff A; Karunakaran D; Chacon JE; Kiser PF
Pharm Res; 2020 Apr; 37(4):83. PubMed ID: 32296951
[TBL] [Abstract][Full Text] [Related]
6. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
Barrett SE; Teller RS; Forster SP; Li L; Mackey MA; Skomski D; Yang Z; Fillgrove KL; Doto GJ; Wood SL; Lebron J; Grobler JA; Sanchez RI; Liu Z; Lu B; Niu T; Sun L; Gindy ME
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012772
[TBL] [Abstract][Full Text] [Related]
7. Treatment and prevention of HIV infection with long-acting antiretrovirals.
Benítez-Gutiérrez L; Soriano V; Requena S; Arias A; Barreiro P; de Mendoza C
Expert Rev Clin Pharmacol; 2018 May; 11(5):507-517. PubMed ID: 29595351
[TBL] [Abstract][Full Text] [Related]
8. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.
Jacobson JM; Flexner CW
Curr Opin HIV AIDS; 2017 Jul; 12(4):343-350. PubMed ID: 28368868
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting HIV Drugs for Treatment and Prevention.
Gulick RM; Flexner C
Annu Rev Med; 2019 Jan; 70():137-150. PubMed ID: 30355266
[TBL] [Abstract][Full Text] [Related]
10. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.
Cobb DA; Smith NA; Edagwa BJ; McMillan JM
Expert Opin Drug Deliv; 2020 Sep; 17(9):1227-1238. PubMed ID: 32552187
[TBL] [Abstract][Full Text] [Related]
11. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
Gulick RM
Top Antivir Med; 2018 Apr; 25(4):127-132. PubMed ID: 29689540
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.
Wu VH; Smith RA; Masoum S; Raugi DN; Ba S; Seydi M; Grobler JA; Gottlieb GS;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559249
[TBL] [Abstract][Full Text] [Related]
15. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
16. Investigational reverse transcriptase inhibitors for the treatment of HIV.
Cory TJ; Midde NM; Rao P; Kumar S
Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
19. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones.
Li L; Gatto GJ; Brand RM; Krovi SA; Cottrell ML; Norton C; van der Straten A; Johnson LM
J Control Release; 2021 Dec; 340():188-199. PubMed ID: 34678316
[TBL] [Abstract][Full Text] [Related]
20. Long-acting rilpivirine for HIV prevention.
Jackson A; McGowan I
Curr Opin HIV AIDS; 2015 Jul; 10(4):253-7. PubMed ID: 26049950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
